Welcome to our dedicated page for Verve Therapeutics SEC filings (Ticker: VERV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Verve Therapeutics’ gene-editing disclosures can feel like wading through a lab notebook written in legalese. Risk factors span emerging CRISPR regulations, manufacturing hurdles and multi-million-dollar collaboration terms—details scattered across 300-page 10-Ks and frequent 8-Ks after clinical readouts. If you have ever asked, “Where can I find Verve Therapeutics’ quarterly earnings report 10-Q filing?” or needed Verve Therapeutics insider trading Form 4 transactions before a pivotal PCSK9 data drop, this page ends the search.
Stock Titan’s platform pairs every VERV submission—10-K, 10-Q, 8-K, DEF 14A, S-1 and more—with AI-powered summaries that explain trial milestones, cash runway shifts and licensing economics in plain English. Our engine flags Verve Therapeutics Form 4 insider transactions real-time, highlights executive stock awards in the proxy statement, and answers natural questions like “What does Verve report about ANGPTL3 safety?” With instant alerts, you see each filing the moment it hits EDGAR, then skim concise AI notes instead of scrolling hundreds of footnotes.
Use this hub to: monitor management’s conviction through insider buys, compare R&D spending across quarters, track 8-K material events explained such as FDA clearances, and read a Verve Therapeutics annual report 10-K simplified section that links pipeline timelines to financial forecasts. Whether you’re studying understanding Verve Therapeutics SEC documents with AI for diligence or checking a Verve Therapeutics proxy statement executive compensation discussion, our coverage delivers every detail investors need—no biotech PhD required.
Pentwater Capital Management LP and Matthew Halbower disclosed ownership of 6,720,000 shares of Verve Therapeutics common stock, representing 7.5% of the outstanding class. The filing states this percentage is calculated using 89,143,237 shares outstanding as of May 7, 2025. The shares are directly held by the Pentwater Funds, with Pentwater acting as investment manager and Mr. Halbower identified as the individual connected to the investment manager. The Reporting Persons assert the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Verve Therapeutics (VERV): This Schedule 13G/A amendment reports that the listed Reporting Persons — including Biotechnology Value Fund, L.P., related BVF entities and Mark N. Lampert — no longer beneficially owned any shares of Verve Therapeutics as of the close of business on June 30, 2025. The filing identifies the class as Common Stock (CUSIP 92539P101) and provides reporting persons' addresses and citizenships. All cover-page ownership fields show 0 shares (0%). The amendment is signed by Mark N. Lampert with signature dates of August 14, 2025.
FAQ
What is the current stock price of Verve Therapeutics (VERV)?
What is the market cap of Verve Therapeutics (VERV)?
